4 trends tracked about this subject — the full history, oldest to newest below.
The FDA has approved the first generic version of the HIV-prevention shot lenacapavir, aiming to expand healthcare access for lower-income countries.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Long-acting lenacapavir shows effective HIV PrEP results after a year, raising urgent questions about patient access.
Analysis of South Africa's first Lenacapavir roll-out data emerges alongside global coverage of the twice-yearly HIV prevention shot.